Favipiravir (T-705)

For research use only. Not for use in humans.

Catalog No.S7975

3 publications

Favipiravir (T-705) Chemical Structure

Molecular Weight(MW): 157.1

Favipiravir (T-705) is a potent and selective RNA-dependent RNA polymerase inhibitor, used to treat influenza virus infections.

Size Price Stock Quantity  
USD 107 In stock
USD 397 In stock
USD 997 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Favipiravir (T-705) has been cited by 3 publications

2 Customer Reviews

  • (A) BoDV-1 infection was measured by IFA. BoDV-1 P40 was detected with a primary monoclonal antibody (red), nuclei were stained with DAPI (blue), merged image (scale bars: 50 μm). Favipiravir: T-705

    Cell Physiol Biochem, 2018, 49(1):381-394. Favipiravir (T-705) purchased from Selleck.

    (B) IFA of Vero-rBoDV-1-Gluc cells treated with T-705. Vero-rBoDV-1-Gluc cells were treated as indicated and the cells were stained with an anti-P antibody (shown in green) and DAPI (shown in blue). Bars, 50 μm.

    Antiviral Res, 2017, 143:237-245. Favipiravir (T-705) purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Favipiravir (T-705) is a potent and selective RNA-dependent RNA polymerase inhibitor, used to treat influenza virus infections.
Targets
RNA-dependent RNA polymerase [1]
In vitro

Favipiravir shows anti-influenza virus activities with IC50 ranged from 0.013 to 0.48 μg/ml for the influenza A viruses, from 0.039 to 0.089 μg/ml for the influenza B viruses, and from 0.030 to 0.057 μg/ml for the influenza C viruses. In mammalian cell lines (MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells), Favipiravir shows no cytotoxicity at concentrations up to 1,000 μg/ml. [1] In MDCK cells inoculated with seasonal influenza A (H1N1) viruses, Favipiravir induces lethal mutagenesis. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDCK cells NUHuOHhbTnWwY4Tpc44h[XO|YYm= NHXnO|hKdmirYnn0bY9vKG:oII\pdoFtKHKncHzpZ4F1cW:wIH;mJIlv\my3ZX76ZUBCKH[rcoXzJEhCN0ixbnegT49v\y9{MUOvNFMpUDWQMTmpJIFv\CCrbn\seYVvgmFiQTD2bZJ2eyBqQT;Bco4hSXKkb4KvOk83OCiKMl6yLUkhcHmkcnnkJJZqenW|IHnuJG1FS0tiY3XscJMh[nlibnX1eJJidCC{ZXSgeZB1[WunIHHzd4F6 NY\pT2hJOTdzOUS4N|I>
Vero cells NUGxSmV6TnWwY4Tpc44h[XO|YYm= NWn0U|ZsPy16IHThfZM> NXq3UohQSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUnWwaX6geolzfXNiQ3Hu[IllNTFiaX6gWoVzdyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqenW|LXnu[JVk\WRidnnzeYFtKGO7dH;wZZRpcWNiZX\m[YN1KGGodHXyJFchfG9iODDkZZl{ NFfUdW8yPzZyNk[5NS=>
MDCK cells NYXQenE5TnWwY4Tpc44h[XO|YYm= NHHKOVZKdmirYnn0bY9vKG:oIHnu[ox2\W68YTDBJJZqenW|IDjBM4R2[2txTXnucoV{d3SjL{G1NlUwOTl6MTCoTFVPOSlrIILldIxq[2G2aX;uJIlvKE2GQ1ugZ4VtdHNiYomgcoV2fHKjbDDy[YQhfXC2YXvlJIF{e2G7 M3XmfVE4OTl2OEOy

... Click to View More Cell Line Experimental Data

In vivo In influenza virus-infected mice, Favipiravir (200 mg/kg/day, p.o.) protects the mice from death from influenza virus infection. [1] In mice experimentally infected with Ebola virus, Favipiravir efficiently blocks viral production, reaching an antiviral effectiveness of 95% and 99.6% at 2 and 6days after initiation of treatment, respectively. [3]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells
  • Concentrations: 1000 μg/mL
  • Incubation Time: 3 days
  • Method: The cytotoxicity of T-705 is evaluated by an assay with XTT. XTT is converted to aqueous formazan by an enzyme in MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells. The compounds are diluted to the appropriate concentrations (volume, 100 μl) with test medium (EMEM containing 10% FCS) in 96-well culture plates in which each well contains a concentration of 2 × 103 cells/100 μL. The test plates are incubated for 3 days at 37°C in 100% humidity and 5% CO2. After 3 days, 50 μl of the XTT reagent (1 mg/ml in FCS-free EMEM containing 5 mM phenazine methosulfate) is added, and the reaction product is assayed by measurement of the absorbance at 450 nm with a microplate reader. Cytotoxicity is expressed as the 50% cell-inhibitory concentration (CC50).
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Mice infected with influenza virus A/PR/8/34
  • Formulation: 0.5% methylcellulose
  • Dosages: 200 mg/kg/day
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 31 mg/mL (197.32 mM)
Ethanol 22 mg/mL warmed (140.03 mM)
Water 5 mg/mL warmed (31.82 mM)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 157.1
Formula

C5H4FN3O2

CAS No. 259793-96-9
Storage powder
in solvent
Synonyms N/A
Smiles NC(=O)C1=NC(=CN=C1O)F

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03394209 Completed Drug: Favipiravir|Drug: Oseltamivir 75Mg Capsule Influenza Human|Critical Illness|Influenza Capital Medical University|Beijing Institute of Pharmacology and Toxicology|University of Oxford|Centers for Disease Control and Prevention China February 6 2018 Phase 2
NCT02739477 Terminated Drug: Favipiravir Ebola Virus Survivor Institut National de la Santé Et de la Recherche Médicale France April 2016 Phase 2
NCT02329054 Completed Drug: Favipiravir Ebola Virus Disease Institut National de la Santé Et de la Recherche Médicale France December 2014 Phase 2
NCT02026349 Completed Drug: favipiravir|Drug: Placebo Influenza MDVI LLC|MediVector Inc. January 2014 Phase 3
NCT02008344 Completed Drug: favipiravir|Drug: placebo Influenza MDVI LLC|MediVector Inc. December 2013 Phase 3
NCT01728753 Completed Drug: Placebo|Drug: Favipiravir Influenza MDVI LLC|United States Department of Defense November 2012 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Favipiravir (T-705) | Favipiravir (T-705) supplier | purchase Favipiravir (T-705) | Favipiravir (T-705) cost | Favipiravir (T-705) manufacturer | order Favipiravir (T-705) | Favipiravir (T-705) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID